Pfizer Inc. named oncology chief and company veteran Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been searching ...

Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D, as the company faces down criticism of its recent efforts to develop and build its pipeline. He is ...

The unit is led by Chris Boshoff, a longtime Pfizer executive who most recently served as the company's head of cancer research and development. "As a newly combined organization, our expertise ...

Chris Boshoff, Pfizer’s chief oncology officer Its new chief oncology officer, Dr Chris Boshoff, said the focus will be on four main cancer types: breast cancer, genitourinary cancers including ...

After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor.

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow sales in the years ahead.

Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and antibody-drug conjugate franchises alongside potential financial impacts ...